To eliminate hepatitis C in people with HIV in Scotland, healthcare providers will need to reach people not on HIV treatment and step up testing for hepatitis C in people who inject drugs, an analysis of Scottish surveillance data published in HIV Medicine shows. Scotland has a high prevalence of hepatitis C among people with… Read More »
People with HIV who already have resistance to a non-nucleoside reverse transcriptase inhibitor (NNRTI) when they start first-line antiretroviral treatment containing the integrase inhibitor dolutegravir were less likely to achieve viral suppression, a large clinical trial in South Africa has reported. NNRTI resistance has not been shown to affect responses to dolutegravir-based treatment previously. The… Read More »
A US study has concluded that weight gain is greater by around 2 to 4 kg in HIV-positive people taking bictegravir or dolutegravir as part of their first antiretroviral therapy (ART), compared to their counterparts using other drug regimens. A similar effect was reported in those using the protease inhibitor darunavir. The study led by… Read More »
There are ethnic disparities in relation to two key indicators of the quality of HIV care, but there are no differences in viral suppression within a year of starting treatment, Dr Rageshri Dhairyawan told the virtual British HIV Association (BHIVA) conference yesterday. Although the differences are not large, dealing with them is necessary if the… Read More »
LONDON, 30th October, 2020 – Cornerstone OnDemand (NASDAQ: CSOD), a global leader in people development solutions, today announces it has been recognised as a Strategic Leader in the new 2020 Fosway 9-Grid™ for Talent & People Success. “We believe that when people bring their best to work, success follows. We will work tirelessly to make… Read More »